| 货号 | DB058018 |
|---|---|
| 品牌 | abinScience |
| 样本类型 | Plasma, Serum |
| 灵敏度 | 0.156 μg/ml |
| 检测范围 | 0.31-5 μg/mL |
| Accession号 | P13726 |
| 应用 | ELISA |
| 检测方法 | Colorimetric |
| 实验类型 | Quantitative |
| 回收率 | 80-120% |
| 运输 | 2-8 ℃ |
| 稳定性和存储 | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| 规格 | Tisotumab |
| 别名 | HuMax-TF-ADC, TF-011-MMAE, HuMax-TF, CAS: 1418628-81-5 |
| 背景 | Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Based on its high expression on many solid tumors (including ovarian, prostate, bladder, esophageal, endometrial and lung) and its rapid internalization, TF is considered a suitable target for antibody-drug conjugates. In pre-clinical trials tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth. Genmab and Seattle Genetics are jointly developing tisotumab vedotin. In a Phase IIa study, preliminary data demonstrated a manageable safety profile and encouraging efficacy (ORR 37%) in relapsed, recurrent or metastatic cervical cancer. |
| Note | For Research Use Only. |
027-87433958/17302791434
武汉东湖新技术开发区神墩四路666号研发楼B区3层东
